FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3090456423> ?p ?o ?g. }

• W3090456423 endingPage "S65" @default.
• W3090456423 startingPage "S64" @default.
• W3090456423 abstract "Introduction In the pivotal ATTR-ACT study, tafamidis was associated with a 30% lower mortality risk than placebo (PBO) in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) over 30 months. Because patients receiving PBO in ATTR-ACT switched to tafamidis in the ongoing, open-label long-term extension (LTE), the long-term efficacy of tafamidis cannot be directly compared with PBO. A statistical extrapolation method has been used to estimate between-group differences in survival beyond the 30-month trial duration. Hypothesis Comparing observed long-term survival with tafamidis in the LTE with estimated survival with PBO extrapolated from ATTR-ACT will allow fuller assessment of tafamidis survival benefits. Methods In ATTR-ACT, patients with ATTR-CM received tafamidis (80 or 20 mg) or PBO for 30 months. In the LTE, patients previously receiving tafamidis continued on the same tafamidis dose, and those previously receiving PBO were randomized to tafamidis 80 mg or 20 mg. Based on a protocol amendment (July 20, 2018), all patients in the LTE transitioned to tafamidis free acid 61 mg (bioequivalent to tafamidis 80 mg). All-cause mortality was assessed using a Cox proportional hazards model for tafamidis 80/61 mg or PBO/tafamidis in ATTR-ACT/LTE. A gamma model based on patient-level data for the PBO group in ATTR-ACT and best model fitting criteria (AIC, BIC) was used to extrapolate survival beyond 30 months. Results In this interim analysis of all-cause mortality, 75/176 (42.6%) and 108/177 (61.0%) patients in the tafamidis 80/61 mg and PBO/tafamidis groups, respectively, died (median follow-up: 51.9 and 51.4 months). Long-term continuous tafamidis treatment was superior to PBO/tafamidis treatment (Figure). Mortality risk was reduced by 41.1% with tafamidis 80/61 mg (n = 176) vs PBO/tafamidis (n = 177) (hazard ratio, 0.5888 [95% CI: 0.4370-0.7931]; P = 0.0004). In the extrapolated PBO group, the estimated median overall survival was 35.2 months, vs 35.8 months in the observed PBO/tafamidis group. The curves for PBO/tafamidis and estimated PBO diverged after ∼44 months in favor of tafamidis. Conclusions Extrapolation of PBO data from ATTR-ACT was a valuable tool allowing comparison of potential outcomes with and without tafamidis treatment. Although these extrapolated data suggest that delayed initiation of tafamidis may provide some survival benefit, early continuous treatment with tafamidis results in significantly better survival outcomes in patients with ATTR-CM." @default.
• W3090456423 created "2020-10-08" @default.
• W3090456423 creator A5005444348 @default.
• W3090456423 creator A5023195809 @default.
• W3090456423 creator A5026643809 @default.
• W3090456423 creator A5064491154 @default.
• W3090456423 creator A5072877047 @default.
• W3090456423 creator A5083295306 @default.
• W3090456423 date "2020-10-01" @default.
• W3090456423 modified "2023-09-23" @default.
• W3090456423 title "Long-term Survival Benefit of Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy" @default.
• W3090456423 doi "https://doi.org/10.1016/j.cardfail.2020.09.190" @default.
• W3090456423 hasPublicationYear "2020" @default.
• W3090456423 type Work @default.
• W3090456423 sameAs 3090456423 @default.
• W3090456423 citedByCount "0" @default.
• W3090456423 crossrefType "journal-article" @default.
• W3090456423 hasAuthorship W3090456423A5005444348 @default.
• W3090456423 hasAuthorship W3090456423A5023195809 @default.
• W3090456423 hasAuthorship W3090456423A5026643809 @default.
• W3090456423 hasAuthorship W3090456423A5064491154 @default.
• W3090456423 hasAuthorship W3090456423A5072877047 @default.
• W3090456423 hasAuthorship W3090456423A5083295306 @default.
• W3090456423 hasConcept C121157162 @default.
• W3090456423 hasConcept C121332964 @default.
• W3090456423 hasConcept C126322002 @default.
• W3090456423 hasConcept C142724271 @default.
• W3090456423 hasConcept C143998085 @default.
• W3090456423 hasConcept C164705383 @default.
• W3090456423 hasConcept C2777633098 @default.
• W3090456423 hasConcept C2778198053 @default.
• W3090456423 hasConcept C2778797674 @default.
• W3090456423 hasConcept C61797465 @default.
• W3090456423 hasConcept C62520636 @default.
• W3090456423 hasConcept C71924100 @default.
• W3090456423 hasConceptScore W3090456423C121157162 @default.
• W3090456423 hasConceptScore W3090456423C121332964 @default.
• W3090456423 hasConceptScore W3090456423C126322002 @default.
• W3090456423 hasConceptScore W3090456423C142724271 @default.
• W3090456423 hasConceptScore W3090456423C143998085 @default.
• W3090456423 hasConceptScore W3090456423C164705383 @default.
• W3090456423 hasConceptScore W3090456423C2777633098 @default.
• W3090456423 hasConceptScore W3090456423C2778198053 @default.
• W3090456423 hasConceptScore W3090456423C2778797674 @default.
• W3090456423 hasConceptScore W3090456423C61797465 @default.
• W3090456423 hasConceptScore W3090456423C62520636 @default.
• W3090456423 hasConceptScore W3090456423C71924100 @default.
• W3090456423 hasIssue "10" @default.
• W3090456423 hasLocation W30904564231 @default.
• W3090456423 hasOpenAccess W3090456423 @default.
• W3090456423 hasPrimaryLocation W30904564231 @default.
• W3090456423 hasRelatedWork W2003247625 @default.
• W3090456423 hasRelatedWork W2004547908 @default.
• W3090456423 hasRelatedWork W2281034034 @default.
• W3090456423 hasRelatedWork W2902785666 @default.
• W3090456423 hasRelatedWork W2919694887 @default.
• W3090456423 hasRelatedWork W2920741594 @default.
• W3090456423 hasRelatedWork W2983833521 @default.
• W3090456423 hasRelatedWork W3201259120 @default.
• W3090456423 hasRelatedWork W3217667383 @default.
• W3090456423 hasRelatedWork W4255778818 @default.
• W3090456423 hasVolume "26" @default.
• W3090456423 isParatext "false" @default.
• W3090456423 isRetracted "false" @default.
• W3090456423 magId "3090456423" @default.
• W3090456423 workType "article" @default.